Dermata Therapeutics
DRMA
10 hedge funds and large institutions have $119K invested in Dermata Therapeutics in 2022 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 1 increasing their positions, reducing their positions, and 3 closing their positions.
33% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 3
18% more capital invested
Capital invested by funds: $101K → $119K (+$17.8K)
11% more funds holding
Funds holding: 9 → 10 (+1)
0.47% more ownership
Funds ownership: 1.95% → 2.42% (+0.47%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RJFSA
Raymond James Financial Services Advisors
St. Petersburg,
Florida
|
+$74K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$12.5K |
| 3 |
FWP
FAS Wealth Partners
Leawood,
Kansas
|
+$6.27K |
| 4 |
TSS
Two Sigma Securities
New York
|
+$6.27K |
| 5 |
HA
HC Advisors
Sandy Springs,
Georgia
|
+$5.01K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VF
Virtu Financial
New York
|
-$37K |
| 2 |
Jane Street
New York
|
-$12K |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$5K |
DRMA Hedge Fund Activity: Q4 2022 in Review
10 of the 6,239 institutional investors tracked by Wall St. Rank reported a position in Dermata Therapeutics (DRMA) for Q4 2022, worth a combined $119K — up 18% from $101K a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new DRMA positions and 3 closed out — a net gain of 1 holder — while 1 added to existing stakes and 0 trimmed.
The largest buyer was Raymond James Financial Services Advisors, opening a new position worth an estimated $74K. The largest seller was Virtu Financial, exiting entirely with an estimated $37K sold.
- 10 institutional investors held Dermata Therapeutics (DRMA) as of Q4 2022, up from 9 in Q3 2022.
- Funds reported $119K of Dermata Therapeutics stock for Q4 2022, up 18% quarter-over-quarter.
- 4 funds opened new Dermata Therapeutics positions in Q4 2022 and 3 closed out, a net change of +1 holder.
- The largest Dermata Therapeutics buyer in Q4 2022 was Raymond James Financial Services Advisors, an estimated $74K added.
- The largest Dermata Therapeutics seller in Q4 2022 was Virtu Financial, an estimated $37K sold.
Based on aggregated 13F filings for Q4 2022.